| 摘要 |
[摘 要]探讨丙戊酸镁治疗伴攻击行为的精神分裂症的疗效及安全性。方法 选取我院于2014年4月至2017年6月期间收治的64例伴攻击行为的精神分裂症患者，按照随机数字表法将所有患者随机分为对照组和试验组两组，每组患者各32例。其中对照组患者均服用奥氮平进行常规治疗，而试验组患者则在对照组的治疗基础上联合使用丙戊酸镁进行治疗。分析两组患者治疗前后的精神症状评分（Tipical Psychiatric Rating Scale,TPRS）和外显行为攻击评分（Modified Overt Aggression Scale,MOAS）、副反应量表评分（Treatment Emergent Symptom Scale,TESS）等评分情况，比较两组患者的不良反应发生情况。结果 对照组患者的MOAS评分和TPRS评分在治疗2周后才有所改善，而试验组患者的MOAS评分和TPRS评分咋在治疗1周后即开始有所改善，并且治疗1周后直至治疗4周后，试验组患者的MOAS评分和TPRS评分均显著低于对照组患者（t=4.836，t=4.092，t=2.293，t=1.993，t=2.038，t=1.973，均P＜0.05）。对照组患者治疗2周后和治疗4周后的TESS评分均显著高于试验组患者（t=2.235，t=2.783，均P＜0.05）。试验组患者的不良反应发生率为9.38%，显著低于对照组患者的34.38%（χ2=5.938，P＜0.05）。结论 丙戊酸镁治疗伴攻击行为的精神分裂症能够有效改善患者的外显行为和精神症状，其治疗效果及安全性均较常规治疗有显著提升，值得在临床上加以推广运用。
|
| Abstract |
[Abstract]Objective To investigate the efficacy and safety of magnesium valproate in the treatment of schizophrenia with aggressive behavior. Methods Selected from April 2014 to June 2017 were analyzed in 64 cases with aggressive behavior of patients with schizophrenia, according to random number table method to all of the patients were randomly divided into two groups, control group and test group 32 cases in each group of patients. The control group was treated with olanzapine for routine treatment, while the experimental group was treated with magnesium valproate in combination with the treatment of the control group. Analysis of the two groups before and after Treatment in patients with mental Symptom scores (Tipical Psychiatric Rating Scale,TPRS) and explicit behavior attack Rating (Modified Overt Aggression Scale, MOAS), Scale score (Treatment Emergent Symptom Scale, TESS) such as grading, compared two groups of patients with adverse reactions occur. Results Control patients MOAS score and TPRS score at 2 weeks after treatment was improved, and the experimental group patients MOAS score and TPRS scoring zha in 1 week after treatment began to improve, and after 1 week until 4 weeks after treatment, the treatment group patients MOAS score and TPRS scores were significantly lower than the control group patients (t = 4.836, t = 4.092, t = 2.293, t = 1.993, t = 2.038, t = 1.973, P < 0.05). The TESS score of the control group after 2 weeks and after 4 weeks was significantly higher than that in the experimental group (t = 2.235, t= 2.783, all P < 0.05). The incidence of adverse reactions was 9.38%, significantly lower than 34.38% in the control group (χ2= 5.938, P < 0.05). Conclusion Schizophrenia can effectively improve the patients explicit behavioral and psychological symptoms of magnesium valproate in the treatment of patients with aggressive behavior of the spirit, its therapeutic effect and safety were compared with routine treatment were significantly improved, it is worth to be popularized in clinical application.
|